title: Effect of white mineral trioxide aggregate compared with biomimetic carbonated apatite on dentine bridge formation and inflammatory response in a dental pulp model.
abstract: OBJECTIVE
  To evaluate the effects of apatite precipitation on the biocompatibility and hard tissue induction properties of white mineral trioxide aggregate (WMTA) in a dental pulp model.
  
  
  METHODS
  Pulp exposures were created on the axial walls of 32 sound canine teeth of eight dogs. Four additional sound teeth served as controls. The pulps were capped either with WMTA or apatite derivatives [biomimetic carbonated apatite (BCAp)] in the interaction of WMTA with a synthetic tissue fluid and restored with zinc oxide-eugenol cement. After 7 and 70 days, the animals were killed, and the histological specimens taken from the teeth were stained with haematoxylin and eosin for histomorphological evaluation. The Brown and Brenn technique was employed to stain bacteria. The data were subjected to nonparametric Kruskall-Wallis analysis and Mann-Whitney U_tests.
  
  
  RESULTS
  Biomimetic carbonated apatite did not induce hard tissue bridge formation. WMTA performed significantly better than BCAp in this respect at both periods (P < 0.05). BCAp was associated with a significantly greater inflammatory response as compared with WMTA after 7 days (P < 0.05). Both materials were associated with similar reactions after 70 days (P >0.05).
  
  
  CONCLUSIONS
  White mineral trioxide aggregate induced hard tissue formation via a mechanism other than that postulated via apatite formation.
authors: Dental Research Center, Tehran University of Medical Sciences, Tehran, Iran. fdde44@yahoo.com
authors: F
authors: F
authors: Danesh
authors: A
authors: A
authors: Vahid
authors: J
authors: J
authors: Jahanbani
authors: F
authors: F
authors: Mashhadiabbas
authors: E
authors: E
authors: Arman
mesh_terms: D017607:Aluminum Compounds / Q000627:therapeutic use*; D000818:Animals; D001031:Apatites / Q000627:therapeutic use*; D001672:Biocompatible Materials / Q000627:therapeutic use; D040761:Biomimetic Materials / Q000627:therapeutic use*; D017610:Calcium Compounds / Q000627:therapeutic use*; D003481:Cuspid / Q000187:drug effects; D003782:Dental Pulp / Q000187:drug effects* / Q000473:pathology; D003789:Dental Pulp Exposure / Q000188:drug therapy; D003793:Dental Restoration, Permanent / Q000379:methods; D003809:Dentin, Secondary / Q000187:drug effects* / Q000473:pathology; D004195:Disease Models, Animal; D004285:Dogs; D004338:Drug Combinations; D008297:Male; D008768:Methylmethacrylates / Q000737:chemistry; D010087:Oxides / Q000627:therapeutic use*; D057872:Pulp Capping and Pulpectomy Agents / Q000627:therapeutic use*; D011671:Pulpitis / Q000473:pathology*; D011897:Random Allocation; D017640:Silicates / Q000627:therapeutic use*; D013997:Time Factors; D015035:Zinc Oxide-Eugenol Cement / Q000737:chemistry
chemical_list: D017607:Aluminum Compounds; D001031:Apatites; D001672:Biocompatible Materials; D017610:Calcium Compounds; D004338:Drug Combinations; D008768:Methylmethacrylates; D010087:Oxides; D057872:Pulp Capping and Pulpectomy Agents; D017640:Silicates; D015035:Zinc Oxide-Eugenol Cement; C086631:mineral trioxide aggregate; C030782:carboapatite; C031667:IRM cement